List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 12 studies with search of:   mage3 | "Nevi and Melanomas"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Terminated Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma
Condition: Malignant Melanoma
Intervention: Biological: MAGE-3.A1 peptide and CpG 7909
2 Active, not recruiting Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug);   Drug: MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
3 Recruiting Melanoma Vaccine With Peptides and Leuprolide
Condition: Melanoma
Interventions: Drug: Leuprolide;   Biological: GP100: 209-217(210M) Peptide;   Biological: MAGE-3 Peptide
4 Completed Vaccine Therapy in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Drug: D1/3-MAGE-3-His fusion protein;   Drug: SB-AS02B adjuvant
5 Completed Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Drug: MART-1 antigen;   Drug: recombinant MAGE-3.1 antigen;   Drug: recombinant interleukin-12
6 Recruiting Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma
Condition: Melanoma (Skin)
Interventions: Drug: MART-1 antigen;   Drug: keyhole limpet hemocyanin;   Drug: recombinant MAGE-3.1 antigen;   Drug: survivin antigen;   Drug: therapeutic autologous dendritic cells
7 Active, not recruiting Vaccine Therapy and Interleukin-12 With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Drug: MART-1 antigen;   Drug: NA17-A antigen;   Drug: aldesleukin;   Drug: gp100 antigen;   Drug: recombinant MAGE-3.1 antigen;   Drug: recombinant interleukin-12;   Drug: therapeutic autologous lymphocytes
8 Active, not recruiting Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
Condition: Melanoma (Skin)
Interventions: Drug: D1/3-MAGE-3-His fusion protein;   Drug: SB-AS02B adjuvant;   Drug: SB-AS15 adjuvant
9 Active, not recruiting Multiepitope Peptide Vaccination in Melanoma
Condition: Metastatic Melanoma
Intervention: Biological: Tyrosinase, MAGE-3, GnTV
10 Completed Peptide Vaccine, Montanide ISA 51 and ISA 51 VG, and CpG 7909 in Treating Patients With Resected Stage IIC, Stage III, or Stage IV Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Drug: agatolimod sodium;   Drug: gp100 antigen;   Drug: incomplete Freund's adjuvant;   Drug: recombinant MAGE-3.1 antigen;   Drug: tyrosinase peptide;   Procedure: adjuvant therapy
11 Completed Vaccine Therapy in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Drug: MART-1 antigen;   Drug: filgrastim;   Drug: flu matrix peptide p58-66;   Drug: gp100 antigen;   Drug: recombinant MAGE-3.1 antigen;   Drug: tyrosinase peptide;   Procedure: in vitro-treated peripheral blood stem cell transplantation
12 Recruiting Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
Conditions: Metastatic Melanoma;   Absence of CNS Metastases
Intervention: Biological: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells

  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services